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Abstract
The development of modern and affordable sequencing technologies has allowed the study of viral populations to an
unprecedented depth. This is of particular interest for the study of within-host RNA viral populations, where variation due to
error-prone polymerases can lead to immune escape, antiviral resistance and adaptation to new host species. Methods to
sequence RNA virus genomes include reverse transcription (RT) and polymerase chain reaction (PCR). RT-PCR is a molecular
biology technique widely used to amplify DNA from an RNA template. The method itself relies on the in vitro synthesis of
copy DNA from RNA followed by multiple cycles of DNA amplification. However, this method introduces artefactual errors
that can act as confounding factors when the sequence data are analysed. Although there are a growing number of
published studies exploring the intra- and inter-host evolutionary dynamics of RNA viruses, the complexity of the methods
used to generate sequences makes it difficult to produce probabilistic statements about the likely sources of observed
sequence variants. This complexity is further compounded as both the depth of sequencing and the length of the genome
segment of interest increase. Here we develop a Bayesian method to characterise and differentiate between likely structures
for the background viral population. This approach can then be used to identify nucleotide sites that show evidence of
change in the within-host viral population structure, either over time or relative to a reference sequence (e.g. an inoculum
or another source of infection), or both, without having to build complex evolutionary models. Identification of these sites
can help to inform the design of more focussed experiments using molecular biology tools, such as site-directed
mutagenesis, to assess the function of specific amino acids. We illustrate the method by applying to datasets from
experimental transmission of equine influenza, and a pre-clinical vaccine trial for HIV-1.
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Introduction
Reverse transcription-polymerase chain reaction (RT-PCR) is a
common tool to generate copy DNA (cDNA) from RNA. All publicly
available sequences of RNA viruses have been generated using this
technique. The method consists of two steps: the first is an in vitro
synthesis of cDNA from an RNA template in a reverse-transcription
reaction (RT); and the second (PCR) consists of multiple cycles of
DNA amplification using the cDNA generated in the RT step as a
template. As in any other polymerisation reaction, misincorporations
that result in artefactual mutations are generated during both steps,
although at different rates (reverse-transcriptases lack proofreading
activity and thus the RT step is more error-prone, while DNA
polymerases exhibit various degrees of proofreading activity).
The current genomics revolution has generated thousands of
sequences of complete RNA viral genomes. Sequences derived
from the influenza viruses resource (http://www.ncbi.nlm.nih.
gov/genomes/FLU/FLU.html) alone account for more than
175,000 as of October 2010. Indeed, the advent of novel and
more affordable sequencing technologies allows the study of viral
populations in an unprecedented depth, up to the level of
characterising within-host viral populations in a qualitative and
quantitative fashion. In particular, such studies are critical to
understand the mechanisms that govern the evolution of virulence
or antiviral resistance, as well as the underpinning mechanisms of
cross-species jumps and immune evasion. In addition, in-depth
studies of genetic variation are increasingly used to elucidate the
viral population dynamics and evolution (phylodynamics) both
within and between hosts [1].
Different laboratories have explored the within-host variation
and evolution of a variety of RNA viruses, ranging from those that
cause acute infections such as influenza and dengue [2–6], to those
that persistently infect their host, like human and simian
immunodeficiency viruses [7–10]. Despite differences in experi-
mental design due to inherent biological features of the virus under
study (i.e. specific host, inoculation route, replication strategy) and
the biological questions being addressed (i.e. size of transmission
bottlenecks, time of appearance of antiviral resistance or immune
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sequences derived from viral samples taken at different times post-
infection. The underlying assumption is that if multiple samples
are taken from a single host over time, it is possible to map the
frequency of a particular observed sequence and its variants in a
temporal fashion. However, since there are various sources of
error, both in the viral replication cycle and in the experimental
process, it is difficult to elicit (probabilistically) whether observed
variants are consistent with the possibility of viral evolution, or
simply a result of random misincorporations occurring either
within the host or during the RT-PCR/sequencing process. We
propose a Bayesian method to try to make such distinctions, and to
illustrate these techniques we use data from an experimental
transmission study of equine influenza virus (EIV) in its natural
host [6], and data from a prime-boost pre-clinical vaccine trial in a
non-human primate model for HIV-1 (M. Varela and J. L.
Heeney, in preparation).
An important biological distinction between these two patho-
gens is the duration of the infection; while influenza infections are
typically acute, lasting for only a few days, HIV infections can last
for a lifetime. In addition, the experimental procedures established
for the study of within-host evolution for those two infections are
different (Figure 1). For HIV, single genome amplification (SGA)
followed by direct sequencing is currently the technique of choice
[7,8,11–15]. In SGA, viral RNA is extracted from a clinical
sample (typically a blood sample) and copied into cDNA, which in
turn is subjected to a limiting dilution step such that only one
molecule is then used as a template for a PCR reaction. Thus the
obtained PCR products are the result of the amplification of one
single molecule of cDNA. These PCR products are then
sequenced directly without cloning. An alternative experimental
approach is clonal sequencing, which has been used to study intra-
host viral populations of influenza and dengue [2,3,5,6]. With this
method, RT-PCR is performed from a clinical sample, followed by
subcloning of the resulting PCR products into sequencing vectors,
which in turn are introduced into bacteria in order to produce the
necessary quantities of DNA required for sequencing. In clonal
sequencing, DNA from individual colonies (i.e. single molecules of
PCR product) are extracted and sequenced.
Thestatisticalframeworkwepresenthereisquitegeneral, and we
showhowitcanbeusedforscreeningdatafromlongitudinalwithin-
host experiments, and/or between-host transmission studies. The
mechanism by which we identify ‘‘sites-of-interest’’ is to monitor the
frequency of bases present at a particular nucleotide site in the
background population of viruses. It should be noted that the
approach we propose here is not meant to replace methods to study
selection analysis, for which there are already many excellent
algorithms and software packages available (e.g. [16]). Instead the
method is designed to flag up single sites that exhibit changes in the
structure of the distributions of bases either over time, or relative to
a reference sequence (such as that obtained from an inoculum
sample). Furthermore it aims to provide a weight-of-evidence in
favour of population structures that suggest higher frequencies of
mutations than would be expected if all mutations arose randomly
without further propagation (i.e. de novo). There are various
biological mechanisms that could cause these observed changes,
for example competition or selection within the host, and we discuss
various options in more detail in the Materials and Methods and
Discussion sections. The method can also be used to inform
subsequent experiments that aim to target the role of individual
nucleotide variants in defined phenotypes. In both studies described
here, viral sequences have been generated using capillary
sequencing technologies (i.e. Sanger sequencing). Although newer
sequencing technologies that produce thousands of reads are
available, they are not yet established for the kind of studies
analysed here. This is due to the variable length of reads they
produce (50to250base pairs), whichmakes itdifficultto link distant
mutations, as well as for the intrinsic error rates they display.
Materials and Methods
Statistical methodology
The genetic units of interest here are individual nucleotide sites,
and the output from the sequencing process is a distribution of
Figure 1. Schematic comparison of clonal vs. SGA sequencing.
doi:10.1371/journal.pcbi.1002027.g001
Author Summary
Characterising genetic variation in viral populations can
have important implications in terms of understanding
how viruses evolve within infected hosts. Modern
sequencing technologies allow genetic information to be
obtained faster, more affordably, and in much greater
quantities than before. This allows new experimental
procedures to be designed to explore aspects of
pathogenesis that were previously unattainable, particu-
larly with regard to mutations that occur at particular
nucleotide sites that may confer a fitness advantage to the
pathogen. This information can be used to study
important issues such as the development of antiviral
resistance, virulence, and/or changes in host-range spec-
ificity. Nonetheless, the experimental procedures used to
generate the data can incorporate artefactual errors, and in
order to optimise the information obtained from these
studies techniques are required to characterise which sites
exhibit mutations that may alter viral fitness. As both the
depth of sequencing increases and the length of the
region sequenced increases (e.g. moves to whole genomes
rather than smaller segments), large numbers of sites will
exhibit some form of variation, and hence development of
a probabilistic method to define and extract these sites-of-
interest becomes more important. We tackle this problem
here using a Bayesian framework.
Bayesian Analysis of Genetic Variation
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consistency we define an observed ‘mutation’ to be a deviation
away from the consensus base at a particular nucleotide site [14].
At a given nucleotide site the consensus is defined as the base
present at the highest frequency in the set of observed sequences
from the inoculum (for the HIV study) or the initial challenge
animal (for the EIV study). In the event that there is no clear
consensus base at a particular site (e.g. a 50:50 split), then
numerically the methods described subsequently are invariant to
the choice of ‘consensus’ and ‘mutation’, though care must be
taken with the biological interpretation of the results.
In the first instance we will consider an individual dataset
containing S sequences of N nucleotides each, derived from a
single clinical sample (in this case a blood sample or a nasal swab).
At any single nucleotide site there are three possible deviations
away from the consensus base. The distributions of observed bases
at a single nucleotide site can then be considered as a random
draw from the background population, and can be described by a
multinomial distribution (described below).
More formally, if we denote the number of bases of type B at site
j as ZjB, then the probability of observing z1 sequences with base
B1, z2 with base B2, z3 with base B3 and z4 with the consensus
base C at position j is:
PZ jB1~z1,ZjB2~z2,ZjB3~z3,ZjB4~z4
  
~
S!
z1!z2!z3!z4!
p
z1
jB1p
z2
jB2p
z3
jB3p
z4
jC,
where
P 4
i~1
zi~S and
P 4
i~1
pi~1. Here the parameters pj~
pjB1,pjB2,pjB3,pjC
  
correspond to the proportion of each base
present in the background population. For brevity we drop the
complex subscript, such that ZjB1,ZjB2,ZjB3,ZjC
  
? Z1,Z2, ð
Z3,Z4Þ and pjB1,pjB2,pjB3,pjC
  
~ p1,p2,p3,p4 ðÞ ; making only the
concession that the consensus base is always indexed 4.
The goal of this work is to develop a screening mechanism to
inform the development of future studies. The proposed method
aims to identify nucleotide sites whose frequency of mutations
differ from their expected values, which in turn are based on a
given viral population and some simple assumptions about the
mechanisms of random mutation events. We aim to approach this
problem by using two main sources of information: the overall
proportion of mutations present in the observed sequences
(denoted p ), and multiple viral samples obtained over time
(and/or within different animals). Given a starting population of
viruses, consider initially the case that all observed mutations occur
randomly without further replication. In this scenario the
distribution of observed bases at a nucleotide site j will be
expected to follow a multinomial distribution such that
P 3
i~1
pji~p ,
regardless of the background structure of the pjis.
On the other hand, if a site j exhibits a frequency of mutations
such that
P 3
i~1
pjiwp , then it is much more likely that some form of
amplification of one or more mutations has occurred, and these
are defined as our ‘‘sites-of-interest’’. Of course in reality p  will
contain both ‘‘unamplified’’ and ‘‘amplified’’ mutations, as it
averages over all positions. Hence using the constraint
P 3
i~1
pjiwp 
to characterise sites-of-interest will be conservative, in the sense
that we are less likely to identify some truly amplified mutations
due to the potential overestimate of p . However, we are not
modelling the biological mechanisms that cause the population
structure p1,p2,p3,p4 ðÞ to change, and therefore it is necessary to
consider the interpretation of sites identified using this criterion.
We note that any mutation must have occurred either by a
biological mechanism (‘‘real’’), or as an artefact of the RT-PCR
process (‘‘artefactual’’), and the aim of this work is to distinguish
between these mechanisms in a viable manner. As in all practical
discrimination algorithms there is the potential for classification
error to happen, and in this case a false positive occurs when an
artefact mutation is classified as a mutation-of-interest, and a false
negative occurs when a real mutation is missed. In fact the distinction
is more subtle than this, since real mutations that are either neutral
or deleterious to the fitness of the virus are not usually of interest
from a biological perspective, and if these occur then they are likely
tobepresentatverylow levelsatany giventimepoint and sowillnot
be isolated via our screening criterion. Of course we also run the risk
of missing real mutations that do confer a fitness advantage but have
only just begun to replicate (i.e. they are present at low levels in the
population). Our method cannot make the distinction between these
‘‘real’’ low frequency mutations and low frequency mutations
occurring as a result of RT-PCR error (without a more complex
mutation model). Instead we argue below that we if we can isolate
highfrequencymutationsina careful way,thenthese aremorelikely
to constitute evidence of providing an increased fitness advantage to
the virus, and hence are of particular biological importance.
Of course, it is possible that single-site mutations that do show
evidence of replication could have arisen during the RT-PCR
process. Although this is theoretically possible, we expect that this
happens at such a negligible level that it is highly unlikely that
mutations isolated during our screening mechanism would have
arisen in this way. For example, in clonal sequencing we amplify a
large population of viruses, and expect that the amplified population
willshowasimilarstructuretotheoriginalpopulation.Ifanythingwe
might expect to miss variants that are present at low levels, since
there is some concern that clonal sequencing might bias towards
pickingupthosevariantspresentathighlevelsinthepopulation[14],
and hence we would be less likely to isolate mutations of this type
using our screening criterion if this were true. In SGA the original
populations are diluted down after reverse transcription in an
attempt to amplify single viral molecules. In this case only mutations
occurring in the RT step would count as artefacts. If an isolated
mutation occursinthe early stepsof the PCR and becomes amplified
in the following cycles, such that it theoretically makes up a large
enough proportion of the amplified population to be detected, then
these sequences are removed from the analysis after visual inspection
of the chromatograms. Thus errors at the PCR step are minimised.
Furthermore, if we sequence multiple clinical samples then the
RT-PCR processes that generate the data will be independent for
each of these samples. Therefore if we saw the same mutation
occurring in multiple clinical samples it is even more unlikely that this
has occurred as an artefact of the RT-PCR. In either case we
acknowledge the possibility that an isolated mutation could be a false
positive, but consider the probability to be negligible. We reiterate
that the methods described here aim to screen the data for sites-of-
interest, and there may well be a small degree of false positive
mutations that creep in; however, an important point is that this false
positive rate will be further mediated if we observe the same mutation
in multiple clinical samples, either from the same or different hosts.
There is an additional subtlety however, and that is that the
background population of viruses in the inoculum may not be
homogeneous, and thus the variation in bases in a set of observed
sequences may simply be a result of sampling from this
Bayesian Analysis of Genetic Variation
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interest to compare the distributions of bases at a particular site to
the distribution in the inoculum, or other earlier viral sample (e.g.
animal source of infection in the EIV study). To this end we
highlight the necessity to model both frequencies and distributions
of mutations. If we were interested purely in the former, then we
could produce the corresponding marginal binomial distribution
modelling the number of mutations observed in a set of sequences.
However, if viral evolution is or has occurred, it is possible that two
viral populations will carry the same frequency of mutations, but of
different types. Therefore we argue here that using a method
based on the full multinomial model allows comparison of the
distributions and frequency of observed mutations, rather than
simply the latter.
To summarise, we have argued so far that we need to:
a) screen for sites that show a higher frequency of mutations
than expected if no propagation of these mutations had
occurred, and in addition
b) screen for sites that show changes in the distribution of bases
compared to earlier viral samples.
These criteria then define a set of ‘‘sites-of-interest’’ that have a
reasonable biological basis for exploration in future studies.
Bayesian model choice
The question then arises as to how to derive a sensible method
to elicit these sites. In a classical statistical framework we would
generate a null hypothesis in each case and then ask the question:
under this null hypothesis how likely are we to see an observation
at least as or more extreme than the observed value? However, it is also
only possible to build evidence against a single null hypothesis, and
yet there are various random substitution models that may be
appropriate [17–19], that would ascribe different structures to the
background population of bases. For example, under the Jukes-
Cantor substitution model [17] the frequencies of the four
nucleotides at equilibrium would be 25%. In reality, a given
nucleotide is much more likely to be miscopied as a transition than a
transversion [19], and although this could be incorporated by setting
different values for the proportions pji i~1,...,3 ðÞ in our null
model, these would have to be known beforehand or estimated
from the data. Here we wish to compare between multiple
competing models, and in addition we also want to compare
between multiple distributions. The Bayesian method we propose
presents a flexible alternative to both of these problems.
Also, often we do not know the specific site of interest in
advance, and in a classical framework it would also be necessary to
account for the number of nucleotide sites being studied. One way
to do this would be to use a multiple correction procedure, such as
the Bonferroni or Holm-Bonferroni corrections (that correct for
the familywise error rate; see e.g. [20]), or the Benjamini-
Hochberg correction (that controls for the false discovery rate;
[21]). The choice of correction procedure depends on the context
of the problem posed; the former are more stringent in protecting
against false positives, whereas the latter allows a proportion of
false positives to be obtained in order to increase the probability of
detecting all true positives. In all cases the degree-of-correction
depends on the number of independent tests (e.g. sites) evaluated.
The approach we propose here uses Bayesian models based on
Bayes’ Factors (BFs; [22–24]). In contrast to the classical statistical
framework where the parameters of the system are assumed fixed,
in a Bayesian framework all parameters are considered to be
random variables with each following a probability distribution. As
such it is possible to analyse competing models in an analogous
way to that of a classical hypothesis test, but with various
advantages, namely:
1. In a classical setting, hypothesis test are set-up to look for
evidence against the null hypothesis; however, they do not
provide weights-of-evidence in favour of the null hypothesis, nor
in relation to competing alternative hypotheses. Both of these
things can be done in a Bayesian framework.
2. If particular nucleotide sites are known in advance to be
associated with the occurrence of non-deleterious or advanta-
geous mutations, then it is possible to incorporate this
information in the form of an increased prior probability of
association.
3. This prior information can be used in an analogous way to
multiple correction procedures, but is invariant to the number
of tests performed, making it suitable for analysing very long
sequences.
4. Useful probability measures, such as the posterior probability of
association (PPA) can be produced to explore different
associations, which are straightforward to interpret and can be
combined to explore composite hypotheses. The PPA in this
context represents the posterior probability that a nucleotide site
exhibits the phenomena of interest (for example, high frequen-
cies of mutations and differences between the distributions of
bases obtained from the inoculum and a specific viral sample).
Other, more general advantages of BFs are described in Kass
and Raftery [23], and an excellent introduction to the use of BFs
in general, but specifically in genetic association studies can be
found in Stephens and Balding [24].
Formally, the BF is defined as the posterior odds in favour of
one model against another, when the prior probability of either
model is equally favourable, and is defined as:
BF~
PD jMi ðÞ
PD jMj
   ,
where Mi and Mj are competing models, and D is the observed
data. We can view the competing models as competing
hypotheses.
The Bayesian framework can be used to generate the PPA for a
given model, and this can be generalised to multiple competing
models. Let k~0,:::,K{1 denote the competing models, and let
PM k ðÞ be the prior probability that model Mk is correct, such that
P K{1
i~0
PM i ðÞ ~1. Then by Bayes’ Theorem:
PM kjD ðÞ ~
PD jMk ðÞ PM k ðÞ
P K{1
i~0
PD jMi ðÞ PM i ðÞ
,
where
PD jMk ðÞ ~
ð
Hk
PD jhk,Mk ðÞ P hkjMk ðÞ dhk,
with hk the (unknown) parameters on parameter space Hk. This
approach therefore integrates, or averages (rather than maximises)
over the parameter space.
If we are looking at multiple nucleotide sites, and PM k ðÞ is equal
acrossallsites, then PM k ðÞ representstheprior proportionofsites that
Bayesian Analysis of Genetic Variation
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population. This is similar to classical multiple testing procedures
that account for the false discovery rate, but has the advantage that
it does not depend on the number of tests performed, only the
proportion of true associations believed to exist in the population [24].
Generating comparative model structures
To attempt to identify sites-of-interest, we will specify a set of
competing models that cover a range of feasible background
population structures. Therefore the set of observed sequences
corresponds to a random draw from one of these population
structures. In many cases we have to resort to numerical methods to
calculate the likelihood, PD jhk,Mk ðÞ , but for the models discussed
here it is possible to derive these analytically (for mathematical
details see Protocol S1). For brevity the subsequent discussion
assumes that we are dealing with a single nucleotide site, and we
drop the site subscript. The observed data at a site are denoted
D~ S,z1,z2,z3,z4 fg , where S is the number of observed sequences.
For a set of sequences obtained from a single dataset (i.e. an
individual clinical sample) we can define ten competing structures
for the background population of bases at a given site. The first
five models cover a range of population structures subject to the
overall mutation rate being equal to p , where p  is the per-
nucleotide mutation probability, i.e. the probability that a
nucleotide in a randomly chosen sequence at a randomly chosen
site differs from the consensus. We estimate p  by computing the
overall proportion of mutations present in the data.
M0 : p1~p2~p3~
p 
3
and p4~1{p :
M1 : p1~p pa, p2~p3~
p pb
2
with pa~1{pb and p4~1{p :
M2 : p2~p pa, p1~p3~
p pb
2
with pa~1{pb and p4~1{p :
M3 : p3~p pa, p1~p2~
p pb
2
with pa~1{pb and p4~1{p :
M4 : p1~p pa, p2~p pb, p3~p pc with pazpbzpc~1
and p4~1{p :
Furthermore, we can also specify an analogous range of models
in which the overall mutation rate p is allowed to vary between 0
and 1.
M5 : p1~p2~p3~
p
3
and p4~1{p:
M6 : p1~ppa, p2~p3~
ppb
2
with pa~1{pb and p4~1{p:
M7 : p2~ppa, p1~p3~
ppb
2
with pa~1{pb and p4~1{p:
M8 : p3~ppa, p1~p2~
ppb
2
with pa~1{pb and p4~1{p:
M9 : p1~ppa, p2~ppb, p3~ppc with pazpbzpc~1
and p4~1{p:
The derivation of PD jMk ðÞ for each of these models is discussed in
Protocol S1and mathematical formsgiven inTableS1, along with R
[25] functions to evaluate these probabilities.
Extension to multiple viral samples
If multiple viral samples are available (i.e. clinical samples
obtained at different times post-infection), D1,:::,DV, then it is
necessary to introduce some additional notation to capture the fact
that different samples could have arisen as a result of sampling
from different background populations. For example, consider that
data from two viral samples from the same animal are available,
denoted D1~ S1,z11,z12,z13,z14 fg and D2~ S2,z21,z22,z23,z24 fg .
There are two possible scenarios: either D1 and D2 are random
samples from the same population, or they are random samples
from different populations. We make the assumption that at any
time the population of bases at a given nucleotide site will be
consistent with one of the models M0,:::,M9, and we denote the
combination of models that could explain the data by using
multiple subscripts corresponding to the viral sample i.e. Mi,j,
where i~0,...,9 corresponds to the population structure for the
first viral sample (D1) and j~0,...,9 to the structure for the
second viral sample (D2).
Thus it is necessary to calculate PD 1,D2jMi,j
  
for any i and j.I f
i=j, then by definition the background populations from which
D1 and D2 are sampled are different, and so PD 1,D2jMi,j
  
~
PD 1jMi ðÞ PD 2jMj
  
—see Protocol S1. When i~j~0 then there
are no free parameters over which to integrate, and so
PD 1,D2jM0,0 ðÞ ~PD 1jM0 ðÞ PD 2jM0 ðÞ .I fi~j=0 then there is
an additional subtlety, in that D1 and D2 are either sampled from
the same population, or from two different populations but with the
same structure. To try to clarify this point, consider Figure 2. This
shows the case when i~j~5. In Figure 2A we see that D1 and D2
are random samples from the same population described by the
model
p
3
,
p
3
,
p
3
,1{p
  
. In Figure 2B we can see that D1 and D2
are random samples from two different populations, but with the
same population structure, described by
pa
3
,
pa
3
,
pa
3
,1{pa
  
and
pb
3
,
pb
3
,
pb
3
,1{pb
  
respectively.
To differentiate between these possibilities we introduce an
additional character subscript such that cases similar to Figure 2A
are denoted Mia,ia and cases similar to Figure 2B as Mia,ib. The
main difference in the calculations of PD 1,D2jMia,ia ðÞ and
PD 1,D2jMia,ib ðÞ relate to the parameter space over which it is
necessary to integrate. These results follow from the fact that
although the background populations are not independent, the
Figure 2. Schematic diagram of sampling from the same or
different populations exhibiting the same population structure
(here based on M5).
doi:10.1371/journal.pcbi.1002027.g002
Bayesian Analysis of Genetic Variation
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S1.
Summarising for the two-sample case, we have PD 1,D2jMi,j
  
given by:
PD 1,D2jMi,j
  
~
P
4
j~1
z1jzz2j
z1j
 !
S1zS2
S1
 ! PD 1zD2jMi ðÞ for i~ia, j~ia,i=0,
PD 1jMi ðÞ PD 2jMj
  
otherwise,
8
> > > > > > > > <
> > > > > > > > :
where D1zD2~ S1zS2,z11zz21,z12zz22,z13zz23,z14zz24 ðÞ .
Hence there are 109 possible competing models that could explain
the joint distribution of D1 and D2, since there are 10|10~100
possible ways of producing random samples from two different
background populations based on structures M0,:::,M9, and a
further 9 ways corresponding to when D1 and D2 are samples from
the same background population (based on M1,:::,M9). It is
possible to generalise these calculations to more than two viral
samples as required, and hence it is possible to produce a PPA for
all possible combinations of potential background structures.
Screening for sites-of-interest
Given sequence data from multiple viral samples, we have
described a method that produces weights-of-evidence in favour of
the data being drawn from a particular configuration of
background populations. In effect these population structures
can be used to define various criteria-of-interest, which can then
be assigned an overall PPA by summing across the relevant
models. This can then be used to provide useful information about
potential changes in the background population of viruses (if any),
and whether or not the frequency of mutations is higher than we
would expect if there had been no propagation of mutations (so all
mutations are first generation). In this case we can combine the
two types of sites we are seeking into a single question that can be
tested using this framework:
‘‘What is the probability that at least one clinical sample
exhibits a higher frequency of mutations than expected if no
propagation of these mutations has occurred, and also shows
a different background structure to the inoculum?’’
To calculate this we can append the inoculum to the observed
data and treat it as an additional sample. We can then sum over
the corresponding model structures that are consistent with the
question of interest. In the two sample case, we have data
DI,D1,D2 ðÞ , where DI is the data for the inoculum (or initial
challenge animal) and we denote the PPA for this definition of site-
of-interest as PPASI, which can be calculated as:
PPASI~
X
i
X
j
X
k
dijkPM i,j,kjDI,D1,D2
  
,
where
dijk~
1i f i=j\j§5 ðÞ | i=k\k§5 ðÞ ,
0 otherwise:
 
It is worth noting here that a range of questions could be asked of
the data, for example we may be more stringent and ask for the
probability that all viral samples obtained from an animal show a
different background structure to the inoculum and exhibit a
higher frequency of mutations than expected if no propagation has
occurred. In which case,
dijk~
1i f i=j\j§5 ðÞ \ i=k\k§5 ðÞ ,
0 otherwise:
 
At the current time we use a brute-force computational approach
to calculate the PPAs for all models, however it would be possible
to develop an approximation based on a variation of the Occam’s
Window approach of [26] in order to make the calculations less
computationally intensive for particularly large-scale problems.
Data and study designs
1. A model of natural transmission of EIV in horses. A
transmission chain was established by experimentally infecting two
horses and housing one of them with two naı ¨ve horses in the same
stable until the ‘‘recipients’’ showed clinical signs of infection. At
that point, the recipient horses were separated and each was
housed together with another pair of horses (Figure 3A). Nasal
swabs were taken from infected animals on a daily basis and viral
RNA was extracted for RT-PCR amplification, subcloning and
further sequencing of individual clones to determine the
mutational spectra of within-host viral populations (for a detailed
account see [6]).
Multiple sequences from each daily sample were generated by
capillary sequencing and compared to the sequence of the seeder
horse. A key aim was to identify single-site mutations arising in
viral samples that were unlikely to simply be artefacts of the
experimental process. It was of particular interest to detect variants
that persisted for multiple days within a host, or were transmitted
between horses.
2. Non-human primate pre-clinical vaccine model for
HIV-1. The aim of this study was to identify specific changes
occurring in the HIV-1 envelope glycoprotein within a host under
selective immune pressure elicited by neutralizing antibodies. To
this end, a prime-boost pre-clinical vaccine trial was performed in
rhesus macaques. Six animals were subjected to a prime-boost
vaccine regime comprising a combination of recombinant gp140
envelopes from clades A, B and C and envelope peptides while
four animals were used as controls (M. Varela and J. L. Heeney,
unpublished results; see Figure 3B). Plasma samples were collected
two and four weeks after challenge with HIV-1SF162 P4 virus stock.
Viral RNA was extracted and envelope genes were PCR amplified
using single genome amplification (SGA) followed by direct
sequencing as previously described [14].
Results
For consistency in this section, we report all the results to two
significant figures (s.f.). Sequences containing insertions were
removed from the data sets, and deletions at particular sites
discounted the number of bases entered into the analysis for that
site.
EIV study
The data in [6] consist of 2366 sequences of length 903
nucleotides, derived from 30 samples taken from 11 horses over a
15-day experiment. The number of sequences derived per sample
ranged from between 44 and 154 sequences, and the breakdown
by individual sample is shown in Table 1.
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variation along the course of infection in single horses and how
transmission can impact on the process of within-host evolution.
As such we can screen the sequence data to identify nucleotide
sites that have specific properties of interest as defined earlier. The
methods described here could help to locate sites and mutations
that confer some fitness advantage, or perhaps neutral selection
through drift founder effects which can also give some insight into
the viral population dynamics.
To calculate the required PPAs it is necessary to specify a prior
probability of association for each of the competing models. We
suggest using a range of priors to assess the strength of any
observed associations. Here we choose values of 0.001, 0.01 and
0.05 in favour of the phenomena of interest (as defined in the
Materials and Methods), split uniformly across all model structures
consistent with being sites-of-interest. The remainder is split
uniformly across all model structures inconsistent with our
definition. Table 3 provides the PPAs that at least one sample
exhibits differences in the background population structure
compared to the initial challenge horse, that also shows a higher
frequency of mutations than we would expect if no replication
occurs (PPASI). It can be seen that even with a very low prior
probabilities (0.001; so less than one site a priori) there are three
sites that show very strong evidence of an association
(PPASI.0.97), and three that show some evidence
(PPASI.0.07).
What this method allows us to do is to observe how the
distributions are changing between samples, which provides useful
Figure 3. Experimental designs for A: EIV, and B: HIV-1 studies. Animal clipart reproduced from www.openclipart.org under the CC0 1.0
Universal Public Domain Dedication license.
doi:10.1371/journal.pcbi.1002027.g003
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course of the experiment. It is therefore possible to explore specific
sites in particular horses in more detail. As an illustrative example
consider site 478 in horse 5447. This had 4 samples taken on days
8–11 (after initiation of the transmission chain), generating 69, 44,
50 and 51 sequences respectively (Table 1). It can be seen that the
only time point at which mutations are observed is on day 11
(Table 4). To model this it is necessary to treat the samples from
the challenge horse as an additional sample (also shown in
Table 1), which results in 210 979 possible sets of models that
could explain the output from the five viral samples. Table 5 shows
the first five models returned after sorting the output by decreasing
PPAs. Notice that the PPAs in favour of each of these models is
equal, and this is because in the situation where there are no
observed mutants in a set of sequences, then there is not enough
information in the data set to distinguish between M0{M4 (see
Table S1). What is driving this pattern is the fact that on day 11
the technique is selecting M7 to be the most likely background
population to have given rise to the data. Hence model M0,0,0,0,7
returns the same PPA as model M1,2,3,4,7, or any other model that
uses structures M0{M4 for the samples from the challenge horse
and days 8–10. It is the sum over all models that have structure 7
on day 11 that is potentially of more interest here, which results in
a marginal probability of 0.54.
We can repeat this for all possible models for day 11, with M9
having a marginal probability of 0.37 and M6 of 0.05. We have
already discussed the likely biological mechanisms behind these
mutations in the Materials and Methods, and these results provide
strong evidence that the mutations observed in position 478 are
likely to indicate real variation and replication within this host
between days 10–11, when mutations of both type G478A and
G478T occur. Interestingly, both G478A and G478T constitute
non-synonymous mutations in a putative antigenic site.
HIV study
The data in the HIV-1 study (M. Varela and J. L. Heeney
unpublished) consist of 439 envelope sequences of length 2544
nucleotides, derived from 10 individuals (plus the inoculum) at two
time points over a four week period (Table 2). The purpose of the
study was to identify specific changes in the HIV-1 envelope
glycoprotein within a host under selective immune pressure
elicited by a prime-boost vaccine. The same questions as for the
EIV study can be asked, though in this case the background
population of viruses in the inoculum is much more heterogeneous
(data not shown) than that from the initial challenge horse in the
EIV study. Table 6 shows the results from those sites with
PPASIw0:05 (with a 0.001 prior). Interestingly, and importantly,
some of these sites are identified in more than one animal, even
though this was not a transmission study. It is also possible to split
the results by vaccination status. Qualitatively at least, the results
in Table 6 suggest that more sites show deviations from the
Table 1. Number of sequences obtained by animal and date
from EIV study [6].
Horse Day nseq
7D36*3 1 5 2
58 2
7248 51 5 4
66 5
71 5 4
86 2
6005 56 7
65 2
77 2
88 1
5447 86 9
94 4
10 50
11 51
7C1C 78 3
87 5
95 2
11 54
5257 71 1 2
81 2 7
2F50 11 49
12 54
13 80
15 46
7A45 11 107
780C 11 71
5D1A 12 54
13 81
14 79
*indicates the first naturally challenged animal.
doi:10.1371/journal.pcbi.1002027.t001
Table 2. Number of sequences obtained by animal and date
from HIV-1 study (M. Varela and J. L. Heeney, in preparation).
Animal Week nseq
Stock*2 2
8758 24 0
41 7
BB204 22 2
48
R00040 22 7
46
R00056 22 9
41 9
R00057 24 2
41 0
R01093 22 4
43 5
R99004 21 9
44 1
R99008 29
41 0
Ri102 21 5
41 7
Ri112 21 2
42 0
*indicates inoculum sequence.
doi:10.1371/journal.pcbi.1002027.t002
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which is suggestive perhaps of increased diversification due to
selection pressure in response to the vaccine.
It is possible as before to delve further into the nature of the
mutations observed, and how the distributions have changed. For
example, consider site 994; this site is identified in three animals
(R01093, BB204 and R99004), two vaccinated and one unvacci-
nated (though the PPA is weaker for the unvaccinated animal). A
summary of bases for each animal at each time point are shown in
Table 7. It is clear to see that there has been a change of consensus
over the time course of infection in each of these animals,
switching from G in the inoculum sample to A in each of the
subsequent samples. This is backed up further by the PPAs for
different model structures (Table 8), in which model M6b,6a,6a was
selected as the most likely model structure in two cases (PPAs of
0.78 and 0.73 respectively) and as the second most likely model
structure in the third (PPA=0.12). In the latter case the most likely
model was M6a,6a,6a (PPA=0.82), which suggests that structure
M6 was the most likely for each sample, but that given the sample
size it was not able to fully disregard the possibility of random
sampling from the inoculum (note that in the HIV-1 study there
were less sequences produced per sample, and hence an increase
in variability in the accuracy of the estimated distributions –
nevertheless more sites-of-interest were identified overall). Of key
importance is the fact that this site was picked up in multiple
animals, and so for reasons discussed previously these differences
are highly unlikely to have arisen as a result of independent RT-
PCR error.
In the EIV study we did not observe any sites that showed
mutations occurring at a high frequency in more than one
sample, however in the HIV-1 study there are various
occurrences of this nature (such as at site 994). It is possible to
screen specifically for these mutations specifically by placing more
stringent criteria on the data; namely that we wish to identify
mutations in which the data show evidence of deviating from the
inoculum in both samples, as well as showing a high frequency of
mutations from the consensus. These are shown in Table 9.
Although the absolute probabilities are different (due to the
resulting change in prior caused by the change in the number of
models-of-interest), the sites observed in Table 9 are all a subset
of those identified in Table 6 (with the exception of site 261 in
animal 8758, which has a low PPA in any case). This illustrates a
practical way in which these methods can be adapted to deal with
specific questions.
Discussion
Obtaining viral genetic information at multiple times post-
infection either along the course of infection or along a chain of
transmission, whether experimental or observational, can help us
to understand the underpinning mechanisms that shape viral
evolution. Nonetheless, it is difficult to obtain probabilistic
information about whether these observed mutations are consis-
tent or inconsistent with having occurred due to random mutation
error. This information can provide insight into the potential
fitness of single-site mutations, both in terms of survival within a
host and transmission between hosts. To this end we have
discussed various ways in which probabilistic measures can be
derived in order to address specific questions regarding the pattern
of observed single-site mutations in the data, and have applied
these measures to two datasets derived from experimental studies
on HIV and influenza. It should be noted that the approach we
propose here is not meant to replace methods to study selection
analysis but to complement them. Indeed, in [6] (for the EIV
study) we estimated the mean numbers of non-synonymous
substitutions per site and synonymous substitutions per site using
the SLAC algorithm available in Datamonkey [16]. Interestingly,
the mutations that we have picked in this manuscript as sites-of-
interest were not identified by the aforementioned selection
analysis. As a result of these more detailed analyses, we are now
more confident than before in the findings of [6], that 4 of the 11
mutations present in individual horses on multiple days were real
(sites 49, 61, 231 and 884; the other 7 identified in [6] were present
in multiple samples but at low frequencies). In addition we picked
up a further two mutations using our screening criteria, at sites 134
and 478. The latter was picked up at one time point in multiple
horses in [6], and the former occurred at one time point in one
horse, and so wasn’t explicitly reported in [6]. However, it
occurred with a high enough frequency of mutations to be
detected here.
Table 3. Posterior probability of association, PPASI, for
different sites from the EIV study.
Horse Position PPASI (0.001) PPASI (0.01) PPASI (0.05)
5447 478 1.0 1.0 1.0
6005 49 1.0 1.0 1.0
6005 884 0.98 1.0 1.0
2F50 231 0.18 0.69 0.92
7248 134 0.09 0.50 0.84
6005 61 0.08 0.47 0.82
Parentheses show the prior probability of association across all models of
interest at a site. Sites shown are those in which the PPASI for the smallest
prior (0.001) is .0.05.
doi:10.1371/journal.pcbi.1002027.t003
Table 4. Frequency of bases for site 478 in horse 5447 in the
EIV study.
Base Challenge horse Day 8 Day 9 Day 10 Day 11
G* 152 69 44 50 37
A 00 0 0 8
C 00 0 0 0
T 00 0 0 6
*Consensus base.
doi:10.1371/journal.pcbi.1002027.t004
Table 5. Summary of models and PPAs for site 478 in horse
5447 from the EIV study.
Model PPA
M0,0,0,7 3:8|10{4
M1,0,0,7 3:8|10{4
M2,0,0,7 3:8|10{4
M3,0,0,7 3:8|10{4
M4,0,0,7 3:8|10{4
. .
. . .
.
doi:10.1371/journal.pcbi.1002027.t005
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sets for mutations of interest, and second, to focus in more detail
on highlighted mutations to elicit information about the change in
background population structure across multiple samples. Whilst it
is possible to generate classical hypothesis tests to tackle certain
questions, we provide a method based on Bayesian model
selection, for various reasons. The first is that it is possible to
generate evidence in favour of a particular hypothesis, rather than
simply weights of evidence against the null hypothesis. Also, it is
possible to compare multiple competing hypotheses in a straight-
forward manner. The Bayesian framework also allows the
inclusion of prior information regarding the probability of specific
individual nucleotide sites to be linked to the occurrence of non-
deleterious or advantageous mutations. When these prior
probabilities take the same values for all sites, then they represent
the prior proportion of sites thought to be associated in some way,
which is similar in principal to the false discovery rate used in
classical multiple correction procedures but is invariant to the
number of sites being examined. This makes it particularly suitable
for analysing long sequences (i.e. those ones generated by capillary
sequencing). In many situations this prior information may not be
available, and so it is necessary to conduct some form of sensitivity
analysis to examine the strength of the posterior association for a
range of prior values. This step helps to shed additional light on
the robustness of the conclusions in the absence of detailed prior
information. Moreover, in this Bayesian approach we integrate
over the range of the unknown parameters, which means that the
structure of the background population has to be specified, but the
proportions do not have to be directly estimated (as would be
necessary in a maximum likelihood framework). This allows for
alternative hypotheses to be generated that assume that multiple
samples can come from either the same, or different background
populations or population structures.
The Bayesian method produces a posterior probability that a
particular hypothesis is true, and can be extended to deal with
Table 6. Posterior probability of association, PPASI, for
different sites from the HIV-1 study.
Unvaccinated Vaccinated
Position (0.001) (0.01) (0.05) (0.001) (0.01) (0.05)
1518 1.0 1.0 1.0
1518 0.27 0.79 0.95
1449 1.0 1.0 1.0
491 1.0 1.0 1.0
2387 1.0 1.0 1.0
994 1.0 1.0 1.0
994 0.99 1.0 1.0
994 0.15 0.64 0.90
1006 1.0 1.0 1.0
1006 0.99 1.0 1.0
1006 0.15 0.64 0.90
1285 1.0 1.0 1.0
1744 1.0 1.0 1.0
1752 1.0 1.0 1.0
1752 1.0 1.0 1.0
1752 1.0 1.0 1.0
2470 1.0 1.0 1.0
2470 1.0 1.0 1.0
449 1.0 1.0 1.0
836 1.0 1.0 1.0
2219 1.0 1.0 1.0
393 1.0 1.0 1.0
393 0.37 0.86 0.97
756 1.0 1.0 1.0
756 0.06 0.39 0.77
433 0.99 1.0 1.0
433 0.14 0.62 0.90
771 0.99 1.0 1.0
771 0.07 0.44 0.80
942 0.99 1.0 1.0
273 0.99 1.0 1.0
2290 0.97 1.0 1.0
2446 0.97 1.0 1.0
750 0.94 0.99 1.0
138 0.89 0.99 1.0
138 0.05 0.35 0.74
1644 0.79 0.97 1.0
418 0.77 0.97 0.99
7 0.74 0.97 0.99
406 0.70 0.96 0.99
406 0.15 0.65 0.90
1305 0.60 0.94 0.99
1305 0.56 0.93 0.99
504 0.39 0.86 0.97
1512 0.39 0.86 0.97
1792 0.31 0.82 0.96
1525 0.31 0.82 0.96
2492 0.26 0.78 0.95
Unvaccinated Vaccinated
Position (0.001) (0.01) (0.05) (0.001) (0.01) (0.05)
680 0.25 0.77 0.95
1347 0.25 0.77 0.95
1479 0.15 0.64 0.90
2007 0.13 0.61 0.89
777 0.11 0.56 0.87
270 0.11 0.54 0.86
386 0.09 0.51 0.85
1668 0.09 0.51 0.85
1134 0.09 0.50 0.84
475 0.09 0.50 0.84
2340 0.09 0.50 0.84
426 0.08 0.48 0.83
445 0.08 0.48 0.83
46 0.06 0.39 0.77
Each line corresponds to a different animal. Values in parentheses show the
prior probability of association across all models of interest at a site and
reported sites are those for which the PPASI with the smallest prior (0.001) is
.0.05.
doi:10.1371/journal.pcbi.1002027.t006
Table 6. Cont.
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suitable range of competing model structures has been developed,
different probabilistic questions can be asked of the data. For
example, when analysing the EIV data we originally screened for
sites that showed evidence of the phenomena-of-interest in at least
one of the samples obtained from one animal. In contrast, in the
case of the HIV-1 data, it was possible to apply more stringent
criteria, which screened for sites that showed evidence of the
phenomena-of-interest in all the samples. An important point is
that the question asked will depend highly on the biological
context of the problem, but the methodology is flexible enough to
allow many probabilistic questions to be posed. It is worth adding
at this point that the same framework could be used to screen for
other types of change. For example, in the HIV-1 study the
population of viruses in the inoculum was highly heterogeneous,
and it would be perfectly possible to screen for initially
heterogeneous sites that revert to a homogeneous population over
time. The only difference would be a change in the definition of
‘‘sites-of-interest’’. In addition it is worth noting that although the
data analysed here have been obtained through experimental
studies, this is not necessary for the methodology to be applied,
though it may alter the interpretation of the results. It would be
perfectly possible to apply the same techniques to observational
data as might be obtained in a real-life disease outbreak.
What this method does not model explicitly are the underlying
mechanisms behind observed systematic mutations. If the
amplification and sequencing steps are faultless and therefore
introduce no errors, then the identified mutations must exist or
occur as part of the replication process in the background viral
population. The techniques described here cannot make the
distinction between low frequency mutations that may have
occurred through viral replication or artefactual error, however
they can help to distinguish between likely deleterious mutations or
non-advantageous mutations and those that show signs of
persistence. It also allows us to compare the distributions of bases
at a given site with other populations, such as the inoculum.
Furthermore, mutations that occur in more than one animal can
happen either de novo within each animal or due to transmission,
Table 7. Frequency of bases for site 994 in animals R01093,
BB204 and R99004 in the HIV-1 study.
Inoculum R01093 BB204 R99004
Wk 2 Wk 4 Wk 2 Wk 4 Wk 2 Wk 4
G* 1 5 000018
A 7 2 43 32 08 1 33 1
C 0 000000
T 0 000000
*Consensus base.
doi:10.1371/journal.pcbi.1002027.t007
Table 8. Summary of models and PPAs for site 994 in animals
R01093, BB204 and R99004 in the HIV-1 study.
R01093 BB204 R99004
Model PPA Model PPA PPA PPA
M6b,6a,6a 0.78 M6b,6a,6a 0.73 M6a,6a,6a 0.82
M9,6a,6a 0.17 M9,6a,6a 0.16 M6b,6a,6a 0.12
M6,9a,9a 0.03 M6,9a,9a 0.05 M9a,9a,9a 0.03
M7,6a,6a 0.01 M6a,6b,6c 0.02 M9,6a,6a 0.02
M8,6a,6a 0.01 M9b,9a,9a 0.02 M6a,6b,6c 0.01
. .
. . .
. . .
. . .
. . .
. . .
.
doi:10.1371/journal.pcbi.1002027.t008
Table 9. Posterior probability of association, PPASI, for
different sites using a more stringent criterion from the HIV-1
study.
Unvaccinated Vaccinated
Position (0.001) (0.01) (0.05) (0.001) (0.01) (0.05)
1449 1.0 1.0 1.0
1518 1.0 1.0 1.0
1518 0.66 0.95 0.99
491 1.0 1.0 1.0
994 1.0 1.0 1.0
994 0.82 0.98 1.0
994 0.43 0.89 0.98
1006 1.0 1.0 1.0
1006 0.82 0.98 1.0
1006 0.43 0.89 0.98
1752 1.0 1.0 1.0
1752 0.97 1.0 1.0
1752 0.90 0.99 1.0
2470 1.0 1.0 1.0
2470 1.0 1.0 1.0
1285 1.0 1.0 1.0
836 1.0 1.0 1.0
756 1.0 1.0 1.0
756 0.23 0.75 0.94
393 0.99 1.0 1.0
393 0.61 0.94 0.99
2290 0.98 1.0 1.0
2446 0.98 1.0 1.0
449 0.94 0.99 1.0
138 0.85 0.98 1.0
1305 0.79 0.97 1.0
1305 0.36 0.85 0.97
2219 0.75 0.97 0.99
504 0.46 0.89 0.98
1512 0.46 0.89 0.98
771 0.39 0.87 0.97
1134 0.32 0.82 0.96
406 0.28 0.80 0.95
750 0.27 0.79 0.95
750 0.09 0.51 0.84
1479 0.15 0.65 0.90
261 0.10 0.54 0.86
Each line corresponds to a different animal. Values in parentheses shown prior
probabilities of association and reported sites are those for which the PPASI
with the smallest prior (0.001) is .0.05.
doi:10.1371/journal.pcbi.1002027.t009
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methods to include information regarding mutations observed in
multiple animals explicitly into the PPA calculations.
As previously mentioned, different techniques (i.e. clonal
sequencing and SGA) are commonly used for the study of HIV
and influenza within-host evolution. Although it is beyond the
scope of this study to argue the relative merits of the two
techniques, it has been argued that SGA provides a more realistic
representation of the viral populations under study as it avoids the
generation of recombinant sequences due to template-switching
and facilitates the detection of Taq polymerase errors [14].
However, this seems to be more important for studies of HIV
than influenza, and since it is time consuming and expensive other
methodologies are normally used to study intra-host evolution of
other viruses. Nonetheless, as highlighted in the introduction, the
experimental process to generate viral sequences is not fully
efficient and so there is a non-zero probability of introducing
artefactual errors. Figure 1 provides a simple schematic diagram
comparing SGA to clonal sequencing, and highlights areas where
errors could be introduced.
Recently there have been some methodological developments in
estimating true mutation rates that account for bias and selection
[27], and it would be possible to change the value of the overall
mutation probability p  to accommodate this. It is worth noting that
in terms of screening for true changes in the distribution of bases at
particular sites as defined here, thevalues of PPASI obtained forthe
within-sample problem will be conservative(i.e. will have a higherfalse
negative rate), since the observed per-nucleotide mutation proba-
bility will include both artefact and real mutations.
It is also possible to conduct various control experiments to
quantify the amount of error that occurs during various steps of
the process. The experimental procedure used to generate the
sequences in [6] included four sequential steps of DNA synthesis
(generation of cDNA, PCR, DNA replication in bacteria and
capillary sequencing). The main issue is determining the level of
artefact mutations introduced during the reverse transcription, as
this is likely to be the principal source of such errors. An issue is
that these errors cannot be easily directly estimated experimentally
as this will require the synthesis of a template RNA population
made of identical RNA molecules, and there is no in vitro
transcription system available that uses enzymes with proofreading
activity. Moreover, the level of RT errors may vary with different
template sequences, intracellular environment, and species origin
of the RT enzyme. As a result it is difficult to draw firm
conclusions as to the levels and sources of non-systematic error
within sequences derived from a single sample without being able
to directly quantify this error. Hence mutants that appear multiple
times may either arise due to mutation events de novo in each
sample, result from transmission from another animal, or be due to
systematic errors in the RT-PCR steps (e.g. if particular sites/
mutations are amplified in a highly non-uniform manner).
However, as we discuss in detail in the Materials and Methods,
there are various reasons that we do not think that we are likely to
pick up changes in the distributions that are purely artefacts of
RT-PCR errors using the screening criteria we introduce here.
The probability of a result being a false positive is further
diminished if a more stringent criteria is used (requiring evidence
across multiple samples), or if similar changes are observed in
multiple animals.
There is also the issue of sampling bias, however there is no
reason to assume that systematic bias should creep into either the
swab sampling or in the RNA extraction. Since, by producing a set
of sequences, we are effectively taking a small sample from a large
population, then the effect of sampling bias (if any) is most likely to
be that rare mutations will constitute a very low probability of
detection and a high probability of being missed during sampling.
Therefore if we do identify sites-of-interest using the criteria
defined here, then it is even more likely that these mutations would
have to be present in reasonably high levels in the background
population to be detected in this manner. This is reflected also in
the increase in variability observed when smaller numbers of
sequences are analysed.
Flexible probabilistic methods such as proposed here can help to
elicit patterns from these complex and large-scale data sets based
on asking intuitive questions about the data. We have described a
method that allows improved inference from studies of viral
transmission and evolution, in particular regarding the probabil-
ities of observing particular mutations in viral sequence data.
These types of study are becoming more common with the advent
of deep and affordable sequencing technologies. Although the
techniques presented here are based on data generated from
capillary sequencing, they form a strong basis for developing
algorithms specifically aimed at data generated by next generation
sequencing technology. For example, sequences obtained using the
Illumina platform can display substantial heterogeneity with
regard to the depth of coverage across the genome segments after
alignment. This means that more information (e.g. samples) will be
available at some sites than others. This heterogeneity in
information is intrinsically incorporated into the PPAs for
individual sites through the Bayesian model specification.
However, it will also be necessary to incorporate additional
sources of error intrinsic to the specific platform being used, and
this is the focus of ongoing work.
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